[
  {
    "ts": null,
    "headline": "AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio",
    "summary": "On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials. The studies did not meet their primary endpoint of showing a statistically significant improvement in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6. Truist says due to the failure, Bristol Myers Squibb & Co’s (NYSE:BMY) Coben",
    "url": "https://finnhub.io/api/news?id=89bf77c8589b89affe635b0dfed2919685f166dd2613c1918a596686fdabfb8d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731437564,
      "headline": "AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio",
      "id": 131324553,
      "image": "https://media.zenfs.com/en/Benzinga/28fb3c69eb8294683e3c24ce9ed6934b",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials. The studies did not meet their primary endpoint of showing a statistically significant improvement in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6. Truist says due to the failure, Bristol Myers Squibb & Co’s (NYSE:BMY) Coben",
      "url": "https://finnhub.io/api/news?id=89bf77c8589b89affe635b0dfed2919685f166dd2613c1918a596686fdabfb8d"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=8f7c78ecd432316ceda2857eaaaa7c21d6f1291dfe7c7da78afddf1ca1bbe0e6",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731429300,
      "headline": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
      "id": 131414142,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=8f7c78ecd432316ceda2857eaaaa7c21d6f1291dfe7c7da78afddf1ca1bbe0e6"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains",
    "summary": "ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY stock rises.",
    "url": "https://finnhub.io/api/news?id=895d02b89eb8f0172499b0b91e516997d8c75fa2e2578f890cfaa8c6d774e46a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731421800,
      "headline": "AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains",
      "id": 131307308,
      "image": "https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY stock rises.",
      "url": "https://finnhub.io/api/news?id=895d02b89eb8f0172499b0b91e516997d8c75fa2e2578f890cfaa8c6d774e46a"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie’s stock plummets over 12% after schizophrenia drug flops in Phase II trials",
    "summary": "The failure of emraclidine, which AbbVie obtained after acquiring Cerevel, may present a considerable advantage for rival BMS.",
    "url": "https://finnhub.io/api/news?id=caba8c03d494e05d885331efd5735acea5aab19f8a9a643c57ac39a7d10e37e1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731417170,
      "headline": "AbbVie’s stock plummets over 12% after schizophrenia drug flops in Phase II trials",
      "id": 131303714,
      "image": "https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/08/abbvie-shutterstock_1935382585.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The failure of emraclidine, which AbbVie obtained after acquiring Cerevel, may present a considerable advantage for rival BMS.",
      "url": "https://finnhub.io/api/news?id=caba8c03d494e05d885331efd5735acea5aab19f8a9a643c57ac39a7d10e37e1"
    }
  },
  {
    "ts": null,
    "headline": "Some Investors May Be Willing To Look Past AbbVie's (NYSE:ABBV) Soft Earnings",
    "summary": "AbbVie Inc.'s ( NYSE:ABBV ) stock was strong despite it releasing a soft earnings report last week. We think that...",
    "url": "https://finnhub.io/api/news?id=4ca07634f4029263ffbca7971a256f6e1e5f3bf7818dd275529b0aaa8a90fac6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731414447,
      "headline": "Some Investors May Be Willing To Look Past AbbVie's (NYSE:ABBV) Soft Earnings",
      "id": 131303716,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/b1235bf6d18ebc2cd7323427468d0693",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc.'s ( NYSE:ABBV ) stock was strong despite it releasing a soft earnings report last week. We think that...",
      "url": "https://finnhub.io/api/news?id=4ca07634f4029263ffbca7971a256f6e1e5f3bf7818dd275529b0aaa8a90fac6"
    }
  },
  {
    "ts": null,
    "headline": "Company News for Nov 12, 2024",
    "summary": "Companies In The News Are: ICL, ARMK, ABBV, SPNS.",
    "url": "https://finnhub.io/api/news?id=88a4105c5a5ea4c6ab8252a45060920b50a00b44c3cb5959d88a5200197f0d1c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731413580,
      "headline": "Company News for Nov 12, 2024",
      "id": 131305620,
      "image": "https://media.zenfs.com/en/zacks.com/6d12ae6d407957348a46f55b412dfc98",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Companies In The News Are: ICL, ARMK, ABBV, SPNS.",
      "url": "https://finnhub.io/api/news?id=88a4105c5a5ea4c6ab8252a45060920b50a00b44c3cb5959d88a5200197f0d1c"
    }
  },
  {
    "ts": null,
    "headline": "What the NFL Draft Can Teach Investors About Big Pharma",
    "summary": "AbbVie’s deal flop and NFL high-profile draft busts have a lot in common.",
    "url": "https://finnhub.io/api/news?id=7e4450b402748ad05b2d4b1fe4f7b57d6a5defd1b9c6f7d124f850f41e2b87c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731412800,
      "headline": "What the NFL Draft Can Teach Investors About Big Pharma",
      "id": 131305621,
      "image": "",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie’s deal flop and NFL high-profile draft busts have a lot in common.",
      "url": "https://finnhub.io/api/news?id=7e4450b402748ad05b2d4b1fe4f7b57d6a5defd1b9c6f7d124f850f41e2b87c2"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say",
    "summary": "AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say",
    "url": "https://finnhub.io/api/news?id=03726f73b83aa7d3d1100520fcc059ba94db53d03f85e1a6077034c7714ead98",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731401580,
      "headline": "AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say",
      "id": 131414143,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say",
      "url": "https://finnhub.io/api/news?id=03726f73b83aa7d3d1100520fcc059ba94db53d03f85e1a6077034c7714ead98"
    }
  },
  {
    "ts": null,
    "headline": "Hungary's Richter CEO reiterates 2024 guidance after strong third quarter",
    "summary": "The CEO of Hungarian pharmaceutical company Richter reiterated 2024 guidance on Tuesday after it reported higher third-quarter revenue and profit. Gabor Orban said pharma revenue and...",
    "url": "https://finnhub.io/api/news?id=bd47c04fdbeb1c50820a6e9365f3f0be0dcc8a6808616b02bb98a30d54c587ac",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731388801,
      "headline": "Hungary's Richter CEO reiterates 2024 guidance after strong third quarter",
      "id": 131300873,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "The CEO of Hungarian pharmaceutical company Richter reiterated 2024 guidance on Tuesday after it reported higher third-quarter revenue and profit. Gabor Orban said pharma revenue and...",
      "url": "https://finnhub.io/api/news?id=bd47c04fdbeb1c50820a6e9365f3f0be0dcc8a6808616b02bb98a30d54c587ac"
    }
  }
]